{
    "nctId": "NCT00575978",
    "briefTitle": "Hydralazine as Demethylating Agent in Breast Cancer",
    "officialTitle": "Hydralazine as Demethylating Agent in Breast Cancer",
    "overallStatus": "WITHDRAWN",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1, PHASE2",
    "allocation": "NA",
    "primaryPurpose": "HEALTH_SERVICES_RESEARCH",
    "enrollmentCount": 0,
    "primaryOutcomeMeasure": "To explore the potency of a clinical tolerable dose of hydralazine as a demethylating agent as indicated.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients referred to the breast cancer service for diagnostic evaluation for \"breast growth\" will be candidates to participate in this study. Patients with history of elevated blood pressure and who are already on anti-hypertensives would be ideal candidates for this project. In such situation, hydralazine will replace other anti-hypertensives. There is no age limit for this study. Inclusion criteria are as follows:\n\n  1. Operable \"invasive\" breast cancer\n  2. Signed informed consent\n  3. Baseline blood pressure OFF antihypertensives \\> 110/60 mmHg\n\nExclusion Criteria:\n\n1. Pre-existing hypotension\n2. Pre-existing liver disease (liver function tests \\> 2x upper limits of normal ULM).\n3. Pre-existing kidney (serum creatinine \\> 2 mg/dl).\n4. Medical necessity to remain on beta-blockers that cannot be met by other agents.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}